Danazol as First-Line Therapy for Myelodysplastic Syndrome

Conclusion Danazol as first-line therapy is an acceptable treatment option with low side effects for patients with MDS who cannot receive ASCT. Micro-Abstract At present, no standard therapy is available for most patients with myelodysplastic syndrome. In this retrospective study, we analyze data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option because of its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research